A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis

BMC Dermatology

Volumn 5, Issue , 2005, Pages

  Mathew, Joseph ^a   Leong, May Y ^a   Morley, Nick ^a   Burt, Alastair D ^b  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOSIDERIN; HYDROCORTISONE; IRON; METHOTREXATE; DERMATOLOGICAL AGENT;

ADULT; ALCOHOLISM; ARTICLE; CASE REPORT; COMORBIDITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG SAFETY; FATTY LIVER; GENE MUTATION; GENETIC ANALYSIS; HEMOCHROMATOSIS; HETEROZYGOSITY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; IRON OVERLOAD; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LONG TERM CARE; MALE; NON INVASIVE MEASUREMENT; PSORIASIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; CHEMICALLY INDUCED DISORDER; FIBROSIS; LIVER; MIDDLE AGED; PATHOLOGY;

DERMATOLOGIC AGENTS; FATTY LIVER; FIBROSIS; HEMOCHROMATOSIS; HUMANS; LIVER; MALE; METHOTREXATE; MIDDLE AGED; PSORIASIS; RISK FACTORS;

EID: 29144505143     PISSN: 14715945     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-5-12     Document Type: Article

References (32)

1. Bjorkman DJ, Hammond EH, Lee RG, Clegg DO, Tolman KG: Hepatic ultrastructure after methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1988, 31:1465-1472.
2. Nohlgard C, Rubio CA, Kock Y, Hammar H: Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. J Am Acad Dermatol 1993, 28:40-45.
3. Jaskiewicz K, Voigt H, Blakolmer K: Increased matrix proteins, collagen and transforming growth factor are early markers of hepatotoxicity in patients on long-term methotrexate therapy. J Toxicol Clin Toxicol 1996, 34:301-305.
4. Hytiroglou P, Tobias H, Saxena R, Abramidou M, Papadimitriou CS, Theise ND: The canals of hering might represent a target of methotrexate hepatic toxicity. Am J Clin Pathol 2004, 121:324-329.
5. Nyfors A: Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand [A] 1977, 85:511-518.
6. Shergy WJ, Polisson RP, Caldwell DS, Rice JR, Pisetsky DS, Allen NB: Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. Am J Med 1988, 85:771-774.
7. Lemann M, Zenjari T, Bouhnik Y, Cosnes J, Mesnard B, Rambaud JC, Modigliani R, Cortot A, Colombel JF: Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000, 95:1730-1734.
8. Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000, 95:3150-3156.
9. Boffa MJ, Chalmers RJ, Haboubi NY, Shomaf M, Mitchell DM: Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal. Br J Dermatol 1995, 133:774-778.
10. Boffa MJ, Chalmers RJ: Methotrexate for psoriasis. Clin Exp Dermatol 1996, 21:399-408.
11. Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO: Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004, 19:391-399.
12. Reynolds FS, Lee WM: Hepatotoxicity after long-term methotrexate therapy. South Med J 1986, 79:536-539.
13. Robinson JK, Baughman RD, Auerbach R, Cimis RJ: Methotrexate hepatotoxicity in psoriasis. Consideration of liver biopsies at regular intervals. Arch Dermatol 1980, 116:413-415.
14. Nyfors A, Poulsen H: Morphogenesis of fibrosis and cirrhosis in methotrexate-treated patients with psoriasis. Am J Surg Pathol 1977, 1:235-243.
15. Langman G, Hall PM, Todd G: Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 2001, 16:1395-1401.
16. Kremer JM, Koff R: A debate: should patients with rheumatoid arthritis on methotrexate undergo liver biopsies? Semin Arthritis Rheum 1992, 21:376-386.
17. Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ: Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996, 10:369-375.
18. Ashton RE, Millward-Sadler GH, White JE: Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982, 79:229-232.
19. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J, De Boo T, Van de Kerkhof PC: Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol 1994, 130:204-210.
20. Lanse SB, Arnold GL, Gowans JD, Kaplan MM: Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/beneflt ratio. Dig Dis Sci 1985, 30:104-109.
21. Kevat S, Ahern M, Hall P: Hepatotoxicity of methotrexate in rheumatic diseases. Med Toxicol Adverse Drug Exp 1988, 3:197-208.
22. Dolan OM, Burrows D, Irvine A, Walsh M: The value of a baseline liver biopsy prior to methotrexate treatment. Br J Dermatol 1994, 131:891-894.
23. British Society of Gastroenterology: Guidelines on the use of liver biopsy in clinical practice; 2004.
24. Coulson IH, McKenzie J, Neild VS, Joseph AE, Marsden RA: A comparison of liver ultrasound with liver biopsy histology in psoriatics receiving long-term methotrexate therapy. Br J Dermatol 1987, 116:491-495.
25. Zachariae H, Aslam HM, Bjerring P, Sogaard H, Zachariae E, Heickendorff L: Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: relation to liver fibrosis and arthritis. J Am Acad Dermatol 1991, 25:50-53.
26. Boffa MJ, Smith A, Chalmers RJ, Mitchell DM, Rowan B, Warnes TW, Shomaf M, Haboubi NY: Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients. Br J Dermatol 1996, 135:538-544.
27. Zachariae H, Heickendorff L, Sogaard H: The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001, 144: 100-103.
28. Mathew J, Burt AD: Cellular mechanisms of fibrogenesis in genetic haemochromatosis. In: Cells of the hepatic sinusoid Edited by Wisse E, vol. 4. pp. 274-276: The Kupffer Cell Foundation, Netherlands; 1993: 274-276.
29. Wojcik JP, Speechley MR, Kertesz AE, Chakrabarti S, PC A: Natural history of C282Y homozygotes for hemochromatosis. Can J Gastroenterol 2002, 16:297-302.
30. Hubscher SG: Iron overload, inflammation and fibrosis in genetic haemochromatosis. J Hepatol 2003, 38:521-525.
31. Whiting-O'Keefe QE, Fye KH, Sack KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90:711-716.
32. Zachariae H, Sogaard H, Heickendorff L: Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies - a further 10-year follow-up. Dermatology 1996, 192:343-346.